Poliomyelitis(polio) is a highly infectious disease caused by the poliovirus often spread from person to person. 25% of the polio infection may manifest flu-like symptoms while a small fraction of individuals may manifest severe symptoms such as paralysis. (ref because you cited statistics of 25%). There is no cure for polio; it can only be prevented by immunization. The polio vaccine, given multiple times, can protect a child for life. With the efforts of the polio eradication program to include polio vaccination as part of the national immunization schedule in all countries, wild poliovirus cases have decreased by over 99% since 1988. There are two types of vaccination available – Inactivated Polio Vaccine and Oral Polio Vaccine.

Inactivated Poliomyelitis Vaccine Made from Sabin Strains (Vero Cell) 

The inactivated poliomyelitis vaccine is the recommended vaccine to be provided to children 2 months and above as a series of 3 doses followed by two booster doses. This is the form that has been included in the national immunization schedule of many countries until they have been declared polio free. 

Our vaccine has been WHO-pre qualified and (insert company details, registration country details)

Oral Poliomyelitis  (Live) Vaccine Type I Type III (Human Diploid Cell)

Oral polio vaccine (OPV) contains an attenuated (weakened) vaccine-virus, activating an immune response in the body. When a child is immunized with OPV, the weakened vaccine-virus replicates in the intestine for a limited period, thereby developing immunity by building up antibodies. During this time, the vaccine-virus is also excreted. In areas of inadequate sanitation, this excreted vaccine-virus can spread in the immediate community (and this can offer protection to other children through ‘passive’ immunization), before eventually dying out. (ref WHO)

Its use was declining in many developed countries due to the risk of vaccine-derived polio where the risk of genetic mutation may outweigh the benefit of herd immunity. Subsequently, the trivalent oral polio vaccine has been replaced with the bivalent oral polio vaccine to reduce this effect as the transmission of wild type II virus has been successfully interrupted. 

Despite the associated rare risk, the OPV is an economical and convenient dosage form for developing countries who still has not achieved polio eradication. In these countries, the small risk of cVDPVs pales in significance to the tremendous public health benefits associated with OPV. Every year, hundreds of thousands of cases due to wild polio virus are prevented. Well over 10 million cases have been averted since large-scale administration of OPV began 20 years ago.

Hence, we still offer the bivalent OPV with Type I and Type III wild poliovirus, studied for children over 2 months old. It has been WHO-prequalified and GMP certified, with exportation to countries such as Pakistan, Zimbabwe, Namibia, South Sudan, Uganda, Chad and many more.